Curis Inc (CRIS)
14.80
+0.03
(+0.20%)
USD |
NASDAQ |
Apr 25, 12:14
Curis Enterprise Value: 30.72M for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 24, 2024 | 30.72M |
| April 23, 2024 | 32.14M |
| April 22, 2024 | 31.19M |
| April 19, 2024 | 28.01M |
| April 18, 2024 | 33.37M |
| April 17, 2024 | 37.68M |
| April 16, 2024 | 33.67M |
| April 15, 2024 | 29.48M |
| April 12, 2024 | 33.73M |
| April 11, 2024 | 37.38M |
| April 10, 2024 | 33.73M |
| April 09, 2024 | 35.50M |
| April 08, 2024 | 40.92M |
| April 05, 2024 | 42.69M |
| April 04, 2024 | 38.03M |
| April 03, 2024 | 22.65M |
| April 02, 2024 | 16.28M |
| April 01, 2024 | 18.40M |
| March 28, 2024 | 7.735M |
| March 27, 2024 | 7.735M |
| March 26, 2024 | 3.138M |
| March 25, 2024 | 7.499M |
| March 22, 2024 | 7.322M |
| March 21, 2024 | 7.499M |
| March 20, 2024 | 4.552M |
| Date | Value |
|---|---|
| March 19, 2024 | 3.904M |
| March 18, 2024 | 3.491M |
| March 15, 2024 | 4.375M |
| March 14, 2024 | 3.727M |
| March 13, 2024 | 4.022M |
| March 12, 2024 | 2.725M |
| March 11, 2024 | 4.670M |
| March 08, 2024 | 5.554M |
| March 07, 2024 | 2.489M |
| March 06, 2024 | 1.192M |
| March 05, 2024 | 4.375M |
| March 04, 2024 | 0.8623M |
| March 01, 2024 | 3.020M |
| February 29, 2024 | 3.727M |
| February 28, 2024 | 1.251M |
| February 27, 2024 | 2.666M |
| February 26, 2024 | 1.310M |
| February 23, 2024 | -0.2811M |
| February 22, 2024 | 1.605M |
| February 21, 2024 | 4.198M |
| February 20, 2024 | 3.432M |
| February 16, 2024 | 5.495M |
| February 15, 2024 | 3.904M |
| February 14, 2024 | 4.316M |
| February 13, 2024 | 3.432M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-55.89M
Minimum
May 24 2022
1.334B
Maximum
May 12 2021
154.93M
Average
25.28M
Median
Jul 25 2023
Enterprise Value Benchmarks
| Kura Oncology Inc | 1.013B |
| AIM ImmunoTech Inc | 9.076M |
| Perspective Therapeutics Inc | 984.38M |
| Protalix BioTherapeutics Inc | 64.08M |
| Armata Pharmaceuticals Inc | 159.15M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.71M |
| Revenue (Quarterly) | 2.696M |
| Total Expenses (Quarterly) | 14.90M |
| EPS Diluted (Quarterly) | -2.03 |
| Gross Profit Margin (Quarterly) | 98.00% |
| Profit Margin (Quarterly) | -434.4% |
| Earnings Yield | -60.54% |
| Normalized Earnings Yield | -60.54 |